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OBJECTIVE — Although it is possible that the association between depression and the met-
abolic syndrome is a “two-way street,” the metabolic syndrome as a predictor of depression has
been little investigated. We examined whether the metabolic syndrome is associated with the
onset of depressive symptoms in a cohort of middle-aged British civil servants.
RESEARCH DESIGN AND METHODS — Analyses included 5,232 participants
(41–61yearsofage)fromtheWhitehallIIprospectivecohortstudy.Depressivesymptomswere
assessed in 1991–1993 and again 6 years later using the depression subscale from the 30-item
General Health Questionnaire. Metabolic syndrome was assessed in 1991–1993, according to
National Cholesterol Education Program criteria.
RESULTS — Presence of the metabolic syndrome was associated with an increased risk of
future depressive symptoms, odds ratio 1.38 (95% CI 1.02–1.96) after adjustment for potential
confounders.Oftheﬁvecomponents,onlycentralobesity,hightriglyceridelevels,andlowHDL
cholesterol levels predicted depressive symptoms. These components explained most of the
association between the metabolic syndrome and the onset of depressive symptoms.
CONCLUSIONS — Our results suggest that the metabolic syndrome, in particular the obe-
sity and dyslipidemia components, is predictive of depressive symptoms.
Diabetes Care 32:499–504, 2009
E
vidence of an association between
depression and cardiovascular dis-
ease (CVD) (1,2) has led some stud-
ies to investigate whether the metabolic
syndrome may constitute an explanatory
mechanism. The metabolic syndrome is
deﬁned as a clustering of risk factors that
predispose an individual to cardiovascu-
lar morbidity and mortality (3,4). It is
characterized by elevated abdominal obe-
sity, high triglycerides, high blood pres-
sure, and high fasting blood glucose
(FBG), and low HDL cholesterol and rep-
resents an important risk factor for CVD
(5). Cross-sectional studies have shown
an association between depression and
the metabolic syndrome in young adults
(6) and in middle-aged populations (7–
9). Cross-sectional associations between
depressive symptoms and individual
components of the metabolic syndrome
have been observed in a North American
study of elderly male twins (10) but were
not evident in a middle-aged cohort from
northern Finland (11). The focus of lon-
gitudinal studies essentially has been to
investigate whether depression predicts
the metabolic syndrome; some have
shown that, in middle aged populations,
depressivesymptomsappeartobeassoci-
ated with an increased risk of the meta-
bolic syndrome in women but not in men
(12,13).
Although in most existing research
the assumption has been that depression
predicts the metabolic syndrome, depres-
sion could also be a consequence of the
metabolicsyndrome.Todate,thisreverse
association has been little investigated.
However, a “two-way street” between de-
pressionandthemetabolicsyndromewas
suggested by ﬁndings from a population-
based prospective cohort study in which
women with the metabolic syndrome in
childhood and adulthood had the highest
level of depressive symptoms in adult-
hood (14). This ﬁnding was not observed
for men. Further evidence was provided
from a cohort of middle-aged women in
which Raikkonen et al. (12) showed that
anger and anxiety increased in response
to the metabolic syndrome. Only one re-
cently published report has investigated
the metabolic syndrome as a risk factor
for depressive symptoms in middle-aged
adults. It showed that the metabolic syn-
drome may be an important factor for the
developmentofdepressioninwomenbut
not in men (15).
Our objective is to investigate pro-
spectively whether the metabolic syn-
drome is associated with the onset of
depressive symptoms in a cohort of mid-
dle-aged British adults free of such symp-
toms at baseline, after taking into account
potential confounders.
RESEARCH DESIGN AND
METHODS— The target population
fortheWhitehallIIstudywasallLondon-
based ofﬁce staff aged 35–55 years and
working in 20 civil service departments
(16). Baseline screening (phase 1) took
place during 1985–1988 (N  10,308)
and involved a clinical examination and
a self-administered questionnaire con-
taining sections on demographic char-
acteristics, health, lifestyle factors, work
characteristics, social support, and life
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measures of blood pressure, anthropom-
etry, biochemical measurements, neu-
roendocrine function, and subclinical
markers of CVD. Subsequent phases of
data collection have alternated between
postal questionnaire alone (phases 2
[1988–1990], 4 [1995–1996], 6 [2001],
and 8 [2006]) and postal questionnaire
accompanied by a clinical examination
(phases 3 [1991–1993], 5 [1997–1999],
and 7 [2002–2004]).
Assessment of metabolic syndrome
at phases 3 and 5
The metabolic syndrome was deﬁned ac-
cording to the criteria of the National
Cholesterol Education Program (NCEP)
(17) based on the presence of three or
more of the following: waist circumfer-
ence 102 cm in men and 88 cm in
women, serum triglycerides 1.7
mmol/l, HDL cholesterol 1.04 mmol/l
inmenand1.29mmol/linwomen,sys-
tolic/diastolic blood pressure 130/85
mmHg,andfastingglucose6.1mmol/l.
Waist circumference was taken as the
smallest circumference below the costal
margin. Resting blood pressure was mea-
sured using the Hawksley Random Zero
Sphygmomanometer. Serum triglycer-
ides, HDL cholesterol, and FBG were an-
alyzed as previously described (18).
Assessment of depressive symptoms
at phases 3 and 5
We assessed depressive symptoms using
the 4-item depression subscale of the 30-
item General Health Questionnaire
(GHQ) (19). The items, obtained on the
basis of factor analysis and comparison
with the items of the depression subscale
ofthe28-itemGHQ(20),are“thinkingof
yourselfasaworthlessperson,”“feltlifeis
entirelyhopeless,”“feltlifeisn’tworthliv-
ing,” and “found at times you couldn’t do
anything because your nerves were too
bad.” All items were scored on a Likert
scale from 0–3 and then summed (range
0–12). Respondents were categorized as
freeofdepressivesymptomsiftheyscored
0–3 or as having depressive symptoms if
theyscored4ormore.New-onsetdepres-
sive symptoms refer to participants who
developed symptoms of depression be-
tweenphases3and5,afterexcludingpar-
ticipants with depressive symptoms at
phase 3. Depressive symptoms assessed
with GHQ cannot be equated with clini-
cally diagnosed depression (21).
Assessment of covariates at phase 3
Sociodemographic variables consisted of
age, sex, ethnicity (white/South Asian/
black),maritalstatus,employmentgrade,
and education. Employment grade, de-
ﬁned on the basis of salary, ranges from 1
to3,withgrade1representingthehighest
level and grade 3 the lowest. Educational
attainment was grouped into ﬁve levels
(noacademicqualiﬁcation,lowersecond-
ary, higher secondary, university degree,
and higher university degree). Health be-
haviors measured were current smoker
(yes/no), alcohol consumption (grams/
day), and intensity of physical activity
(based on frequency and duration of
physical activity and categorized as high,
medium, and low). Prevalent coronary
heart disease (CHD) identiﬁed using clin-
ically veriﬁed events included nonfatal
myocardial infarction and deﬁnite angina
as described previously (22).
Statistical methods
Logistic regression was used to model the
association between the metabolic syn-
drome and each of its components at
phase3andtheonsetofdepressivesymp-
tomsbetweenphases3and5.Inmodel1,
the analyses were adjusted for age, sex,
and ethnicity; in model 2, they were ad-
ditionally adjusted for employment
grade, educational level, marital status,
smoking habit, alcohol consumption,
physical activity, and CHD. Interactions
among the metabolic syndrome and the
covariates(includingsex)weretestedand
were not found to be statistically signiﬁ-
cant at P  0.05.
To assess the extent to which compo-
nentsofthemetabolicsyndromedrivethe
association with depressive symptoms,
we calculated the percent attenuation in
the metabolic syndrome–depressive
symptoms association after the compo-
nents separately associated with depres-
sive symptoms were added to the model.
Thepercentattenuationintheassociation
between the metabolic syndrome and de-
pressive symptoms was determined using
the formula %  {[(x  x adjusted for
w)/x]} 100, where  is the coefﬁcient
estimated from the logistic regression
model.
To further understand the role of the
metabolic syndrome as a risk factor for
the onset of depressive symptoms, we
performedanalysestoexplorewhetherits
components act synergistically by testing
interactions among them. We used a
backward elimination approach that re-
moved all of the 5-, 4-, 3-, and 2-way
interaction terms with P  0.05 from a
saturated model that included all of the
metabolic syndrome components and
their interaction terms. A new variable
combining obesity, high triglyceride, and
low HDL cholesterol components (seven
modalities: 0  none of the component,
1  only obesity, 2  only high triglyc-
eride, 3  only low HDL cholesterol, 4 
obesity and high triglyceride, 5  obesity
and low HDL cholesterol, 6  high tri-
glyceride and low HDL cholesterol, 7 
all three components) was constructed to
test speciﬁcally the combined effects of
these three components on onset of de-
pressive symptoms.
In sensitivity analyses, we excluded
participants with CHD at phase 3 to ex-
plore the contribution of CHD to the
association between the metabolic syn-
dromeandonsetofdepressivesymptoms.
To assess potential bidirectional effects,
we excluded participants free of the met-
abolic syndrome at phase 3 and per-
formed logistic regression analyses
examining associations between depres-
sivesymptomsatphase3andonsetofthe
metabolic syndrome between phases 3
and 5. All analyses were conducted using
SAS software, version 9 (SAS Institute).
RESULTS— Overall, 7,263 individu-
als participated in phase 5. However,
complete data on depressive symptoms at
phases 3 and 5, the metabolic syndrome,
and all the covariates were available for
5,562 participants (1,604 women and
3,958 men) aged 49.5  6.1 years at
phase 3. Of these participants, 330 had
depressivesymptomsatphase3andwere
excluded in order to identify new-onset
depressive symptoms between phases 3
and 5. Compared with those who were
excluded, participants included in the
analysis (n  5,232) were more likely to
bemen(71.5vs.66.2%,respectively)and
younger (49.6  6.08 vs. 49.9  6.06
years, respectively). However, those in-
cluded versus those excluded did not dif-
fer on educational level (participants with
no academic qualiﬁcation: 13.1 vs.
13.7%, respectively) or prevalence of the
metabolic syndrome (10.4 vs. 11.4%, re-
spectively). Prevalence of the metabolic
syndrome in participants who already
had depressive symptoms at phase 3 was
9.7% and was not signiﬁcantly different
fromthatinparticipantsfreefromdepres-
sive symptoms at both phases 3 and 5
(10.2%).
Characteristicsoftheparticipantsasa
functionofthepresenceofmetabolicsyn-
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of the metabolic syndrome was 10.4%
(n  547). Compared with participants
withoutthemetabolicsyndrome,thepro-
portionofparticipantswiththemetabolic
syndrome was lower in women and white
participants but was higher in those with
a low education level and among those
who had low physical activity levels. As
expected, participants with the metabolic
syndrome had higher waist circumfer-
ence, triglycerides, blood pressure, and
FBG levels and a lower HDL cholesterol
concentration than those without the
metabolic syndrome.
After phase 3, 428 participants
(8.2%) developed depressive symptoms,
7.8% of the men and 9.2% of the women.
New-onset depressive symptoms were
more common among participants who
had the metabolic syndrome at phase 3
(13.5 vs. 10.2%, respectively). Further-
more, a higher rate of new-onset depres-
sive symptoms was observed in
participantswiththecentralobesity(14.3
vs. 10.4%), high triglycerides (29.4 vs.
24.9%), and low HDL cholesterol (22.7
vs. 17.8%) components of the metabolic
syndrome.
Table 2 shows multivariate models of
the association between the metabolic
syndrome at phase 3 and onset of depres-
sive symptoms between phases 3 and 5.
In analyses adjusted for sex, ethnicity,
and age, the odds ratio (OR) (95% CI) of
new-onsetdepressivesymptomswas1.47
(1.09–1.99) times higher for participants
with the metabolic syndrome than for
those without. This association remained
statistically signiﬁcant after further ad-
justment for other sociodemographic fac-
tors, health behavior, and CHD: 1.38
(1.02–1.87). Multivariate analyses of the
association between each component of
the metabolic syndrome and onset of de-
pressivesymptomsshowedthatoftheﬁve
componentsonlycentralobesity,hightri-
glyceride levels, and low HDL cholesterol
levelswererelatedtogreateroddsofonset
of depressive symptoms between phases
3and5,whiletherewasnoevidenceofan
association between hypertension and
new-onset depressive symptoms. Unex-
pectedly, participants with elevated FBG
levels were less likely to develop depres-
sive symptoms during the 6-year follow-
up. To examine whether the components
of the metabolic syndrome had an inde-
pendent effect, we included all compo-
nents simultaneously in a model that
included only participants with no
missing data for any of the metabolic
syndrome components (n  4,983 par-
ticipants; n  401 with new-onset de-
pressive symptoms). None of the
components remained signiﬁcantly asso-
ciated with the onset of depressive symp-
toms (obesity 1.28 [0.92–1.77], high
triglycerides 1.20 [0.93–1.56], low HDL
cholesterol 1.19 [0.90–1.56], hyperten-
sion 0.97 [0.77–1.21], high FBG 0.57
[0.32–1.02]).
That nearly half the participants with
metabolic syndrome were obese (49.8%)
raises the possibility that the association
we observed between the metabolic syn-
Table 1—Characteristics of Whitehall participants according to presence of the metabolic
syndrome at phase 3 (1991–1993)
Metabolic syndrome*
No Yes P
n 4,685 547
Women 29.5 20.1 10
4
Age (year) 49.4  6.1 50.7  6.0 10
4
White participants 93.7 91.6 0.002
Single or divorced 19.8 21.0 0.85
Low employment grade 12.5 16.4 0.03
No academic level or lower secondary 45.2 49.3 0.06
Current smoker 11.5 12.2 0.62
Alcohol consumption (ml/day) 12.5  14.1 13.0  15.7 0.48
Low level of physical activity 23.8 27.8 0.002
Waist circumference (cm) 84.2  10.5 98.6  10.0 10
4
Systolic blood pressure 119.2  12.9 131.2  11.6 10
4
Diastolic blood pressure 78.8  8.9 87.8  7.7 10
4
HDL cholesterol 1.48  0.40 1.03  0.25 10
4
Triglycerides 1.26  0.83 2.91  1.52 10
4
FBG 5.18  0.53 5.77  1.31 10
4
CHD 2.3 5.1 10
4
Data are means  SD for continuous variables or percent. *Diagnosis of the metabolic syndrome was based
on the NCEP deﬁnition (ref. 17).
Table 2—Association of the metabolic syndrome at phase 3 with the onset of depressive
symptoms between phases 3 (1991–1993) and 5 (1997–1999)
n; n with new-onset
depressive symptons OR (95% CI) P
Metabolic syndrome 5,232; 428
Model 1 1.47 (1.09–1.99) 0.01
Model 2 1.38 (1.02–1.87) 0.04
Central obesity 5,182; 424
Model 1 1.50 (1.11–2.01) 0.007
Model 2 1.42 (1.06–1.91) 0.02
High triglycerides 5,232; 428
Model 1 1.36 (1.09–1.71) 0.007
Model 2 1.30 (1.03–1.63) 0.02
Low HDL cholesterol 5,232; 428
Model 1 1.33 (1.04–1.69) 0.02
Model 2 1.26 (0.98–1.61) 0.07
Hypertension 5,232; 428
Model 1 1.06 (0.86–1.31) 0.57
Model 2 1.05 (0.85–1.30) 0.66
High FBG 5,049; 406
Model 1 0.58 (0.33–1.04) 0.07
Model 2 0.57 (0.32–1.02) 0.06
Results of logistic regression analyses expressed as OR (95% CI). Model 1 is adjusted for sex, age at phase 3,
and ethnicity. Model 2 reﬂects model 1 additionally adjusted for education, employment grade, marital
status, smoking habits, alcohol consumption, physical activity, and CHD.
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driven mainly by obesity. The percent
attenuation of the association between
the metabolic syndrome and depressive
symptoms by its individual components
was as follows: 37.5% for obesity, 38.0%
for triglycerides, and 23.4% for low HDL
cholesterol. All three components to-
gether explained 93% of the association.
Obesity explained only 20.4% of the rela-
tionship between high triglycerides and
depressive symptoms and 17.8% of the
association between low HDL cholesterol
and depressive symptoms (Table 3).
These ﬁndings provide support for the
hypothesis that the association between
the metabolic syndrome and depressive
symptoms is partly driven by central obe-
sity but that dyslipidemia is also a major
driver.
To test for synergistic effects between
each of the components of metabolic syn-
drome on depressive symptoms, we ex-
amined multiple interaction terms, but
none were statistically signiﬁcant (results
not shown, data available upon request).
However, using a unique variable with all
possible combinations of obesity, high
triglycerides, and low HDL cholesterol,
we found that participants with all three
components were at the greatest risk of
new-onset depressive symptoms, OR
2.71 (95% CI 1.73–4.24).
Sensitivity analyses
Exclusion of participants with CHD at
phase 3 (n  136) had little effect on the
results. After adjusting for sex, ethnicity,
and age, the OR (95% CI) for new-onset
depressive symptoms was 1.37 (1.00–
1.87) times higher for participants with
the metabolic syndrome than for those
without. No support was found for the
hypothesis that depressive symptoms
wereaconsequenceratherthanacauseof
the metabolic syndrome, as there was no
association between presence of depres-
sive symptoms at phase 3 and new-onset
cases of the metabolic syndrome in par-
ticipants free of the metabolic syndrome
at phase 3: 0.89 (0.60–1.33), P  0.57
after controlling for sex, age, and ethnic-
ity, and 0.81 (0.54–1.22) after adjusting
for sociodemographic factors, health be-
haviors,andCHD(resultsnotshown,but
data available upon request).
CONCLUSIONS— Weexaminedas-
sociations between presence of the meta-
bolic syndrome and the onset of
depressive symptoms in a middle-aged
population free of symptoms at baseline.
After adjusting for demographic mea-
sures, socioeconomic factors, health be-
haviors, and prevalent CHD, participants
with the metabolic syndrome had a
higher risk of developing depressive
symptoms 6 years later. Of the compo-
nents of the metabolic syndrome, central
obesity, high triglycerides, and low HDL
cholesterol were the main contributing
factors to this association. There was no
evidence to support bidirectional associ-
ations between the metabolic syndrome
and depressive symptoms.
Among the 5,562 participants in
this study in 1993, prevalence of the
metabolicsyndromeaccordingtoNCEP
criteria was 10.4%. Similar levels of
prevalence were found in a cohort of
healthy middle-aged women in the
Healthy Women Study (9.3% in 1988)
(13) and in a cohort of middle-aged men
participating in the Kuopio Ischemic
Heart Disease Risk Factor Study (11% in
1989) (23). Prevalent CHD is a potential
source of depression, but in the present
study the association between the meta-
bolicsyndromeandnew-onsetdepressive
symptoms remained signiﬁcant after con-
trolling for prevalent CHD and in a sub-
cohort that excluded participants with
this disease. This suggests that the associ-
ation between the metabolic syndrome
anddepressivesymptomsisnotdrivenby
depressive symptoms generated by man-
ifest CHD.
Our ﬁndings are consistent with the
hypothesis that depressive symptoms
may be a consequence rather than a cause
of the metabolic syndrome. Prevalence of
the metabolic syndrome was no higher in
participants with depressive symptoms at
baselinethanamongparticipantswhodid
not have such symptoms at baseline or at
follow-up. This lack of evidence was con-
ﬁrmed in further analyses showing no as-
sociation between presence of depressive
symptomsatbaselineanddevelopmentof
the metabolic syndrome during follow-
up. A corresponding ﬁnding was ob-
served in the Northern Finland 1966
Birth Cohort Study in which the meta-
bolic syndrome deﬁned according NCEP
criteria was not associated with depres-
siveness and anxiousness in 31-year-old
adults (11).
In a middle-aged population–based
sample, Koponen et al. (15) found that
the metabolic syndrome, assessed using
NCEP criteria, was associated with a
higher probability of depressive symp-
toms (measured using the Beck Depres-
sionInventory)aftera7-yearfollow-upin
women but not in men. In another Finn-
ishpopulation–basedstudy,womenwith
themetabolicsyndromeinchildhoodhad
a higher mean depressive symptom score
(Beck Depression Inventory) in adult-
hood, but again no association was found
in men (14). The reasons why these asso-
ciationsshouldbesex-speciﬁcremainun-
clear and are in contrast to our ﬁndings of
anassociationbetweenthemetabolicsyn-
Table3—Contributionoftheobesity,hightriglycerides,andlowHDLcholesterolcomponents
of the metabolic syndrome to the association between the metabolic syndrome and onset of
depressive symptoms
 SE
Reduction in
effect (%)*
Each component alone
Obesity 0.409 0.150 —
High triglycerides 0.294 0.116 —
Low HDL cholesterol 0.263 0.125 —
High triglycerides adjusted for obesity 0.234 0.120 20.4
HDL cholesterol adjusted for obesity 0.216 0.127 17.9
All three components included simultaneously in
the model
Obesity 0.322 0.156 21.3
High triglycerides 0.184 0.130 37.4
Low HDL cholesterol 0.143 0.137 45.6
Metabolic syndrome alone 0.389 0.153 —
Metabolic syndrome adjusted for obesity 0.250 0.175 35.7
Metabolic syndrome adjusted for triglycerides 0.241 0.186 38.0
Metabolic syndrome adjusted for HDL cholesterol 0.298 0.178 23.4
Analyses performed on 5,169 participants (423 with new-onset depressive symptoms). *Compared with a
model not adjusted for any of the factors. , logistic regression coefﬁcient.
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6 years later in both sexes.
An important aspect of our study is
the exploration of the relationship be-
tween each component of the metabolic
syndrome and subsequent onset of de-
pressive symptoms. We found good evi-
dence that central obesity and abnormal
lipids were associated with the onset of
depressive symptoms. However, the hy-
pertensioncomponentwasnotassociated
with subsequent depressive symptoms;
unexpectedly, high levels of FBG were as-
sociated with a lower rather than a higher
probability of depressive symptoms. The
results for central obesity are in concor-
dance with the Alameda County Study,
whichshowedthatobesitywasassociated
with an increased risk of depression 5
years later (24). According to Ross et al.
(25), one explanation of the obesity-
depression relationship could be deval-
uation and stigma that may cause
overweight and obese individuals to suf-
fer from lower self-esteem and a higher
level of depression. Another potential ex-
planation involves unsuccessful weight
control by dieting among obese and over-
weight people that could be more stress-
ful than the obesity per se (25).
It has been argued that the metabolic
syndrome is driven almost entirely by
central obesity. Our results do not sup-
port this position in relation to either the
basic association between the metabolic
syndrome and depressive symptoms or
the associations between the high triglyc-
erides and low HDL cholesterol compo-
nents of the metabolic syndrome with the
onset of depressive symptoms. Thus, the
metabolic syndrome–depressive symp-
toms association does not appear to be
simplyanartifactofthepreponderanceof
obesity in individuals with the syndrome.
While we found no evidence of synergy
among the metabolic syndrome compo-
nentsinpredictingdepressivesymptoms,
our results showed that central obesity,
high triglycerides, and low HDL choles-
terol components had a cumulative effect
on onset. These ﬁndings suggest that a
combinationofcentralobesityandabnor-
mal lipids constitutes a risk factor for
the onset of depressive symptoms. Fur-
ther research on prospective associa-
tions between components of the
metabolic syndrome and the develop-
mentofdepressionisneededtoconﬁrm
our ﬁndings and to explore the mecha-
nisms that underlie the association.
Our study has several potential limi-
tations. First, depressive symptoms were
measured using a short scale that is not a
measure of a clinically recognized psychi-
atric disorder. Although the symptom
scale is reliable, it does not indicate the
severity or the chronicity of the depres-
sion. A second limitation concerns the
limited generalizability of our ﬁndings.
WhitehallIIstudyparticipantsaremainly
white, ofﬁce-based civil servants who are
notfullyrepresentativeoftheBritishpop-
ulation (16). Third, despite the extensive
level of adjustment in our analyses, with
observational data the possibility remains
that unmeasured confounders may ex-
plain part of the association between the
metabolic syndrome and depressive
symptoms.
In conclusion, this is apparently the
ﬁrst study to show that the probability of
new-onset depressive symptoms 6 years
later is higher among men and women
with the metabolic syndrome, an associa-
tionthatremainsaftertakingintoaccount
a large range of potential confounders.
Further research is needed to examine
whether prevention of the metabolic syn-
drome, in particular the obesity and dys-
lipidemia components, might reduce the
onset of depressive symptoms.
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